Wei, S.-H.S.-H.WeiChen, Y.-P.Y.-P.ChenMING-JU CHEN2018-09-102018-09-102015http://www.scopus.com/inward/record.url?eid=2-s2.0-84942525762&partnerID=MN8TOARShttp://scholars.lib.ntu.edu.tw/handle/123456789/390411We hypothesized that probiotics can stimulate enteroendocrine cells to secret glucagon-like peptide-1 (GLP-1) to mitigate the development of type 1 diabetes (T1D). We thus first established a novel screening platform by coculturing lactic acid bacteria with murine enteroendocrine STC-1 cells. Two strains, Lactobacillus kefiranofaciens M (denoted as Strain M) and Lactobacillus kefiri K (denoted as Strain K), were selected according to their capacity to enhance GLP-1 secretion. Administering Strain M and Strain K could alleviate the progression of T1D symptoms in streptozotocin-induced T1D mice model. This T1D-alleviating effect of the selected strains might involve stimulating the secretion of GLP-1, inhibiting the proinflammatory and inflammatory cytokines, elevating the production of IL-10, and modifying the intestinal microbiota. The possible mechanisms that induce Lb. kefiranofaciens M and Lb. kefiri K to stimulate GLP-1 must be further investigated. ? 2015 Elsevier Ltd.GLP-1; Hyperglycaemia; Probiotics; Type 1 diabetes[SDGs]SDG3journal article10.1016/j.jff.2015.08.016